Bibliografie tematiche / Pharmacokinetic interactions

Indice

  1. Articoli di riviste
  2. Tesi
  3. Libri
  4. Capitoli di libri
  5. Atti di convegni
  6. Rapporti di organizzazioni

Letteratura scientifica selezionata sul tema "Pharmacokinetic interactions"

Autore: Grafiati
Pubblicato: 4 giugno 2021
Ultima modifica: 25 luglio 2025

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Pharmacokinetic interactions".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "Pharmacokinetic interactions"

1

Keirns, J., T. Sawamoto, M. Holum, D. Buell, W. Wisemandle, and A. Alak. "Steady-State Pharmacokinetics of Micafungin and Voriconazole after Separate and Concomitant Dosing in Healthy Adults." Antimicrobial Agents and Chemotherapy 51, no. 2 (2006): 787–90. http://dx.doi.org/10.1128/aac.00673-06.

Testo completo
Abstract (sommario):
ABSTRACT We assessed the pharmacokinetics and interactions of steady-state micafungin (Mycamine) or placebo with steady-state voriconazole in 35 volunteers. The 90% confidence intervals around the least-squares mean ratios for micafungin pharmacokinetic parameters and placebo-corrected voriconazole pharmacokinetic parameters were within the 80%-to-125% limits, indicating an absence of drug interaction.
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Taylor, David. "Pharmacokinetic interactions involving clozapine." British Journal of Psychiatry 171, no. 2 (1997): 109–12. http://dx.doi.org/10.1192/bjp.171.2.109.

Testo completo
Abstract (sommario):
BackgroundMetabolism of clozapine is complex and not fully understood. Pharmacokinetic interactions with other drugs have been described but, in some cases, their mechanism is unknown.MethodPublished trials and case reports relevant to the human metabolism of clozapine and to suspected pharmacokinetic interactions were reviewed.ResultsMetabolism of clozapine appears to be largely controlled by the function of the hepatic cytochrome p4501A2 (CYPIA2). Compounds which induce CYPIA2 activity (carbamazepine, tobacco smoke) may reduce plasma clozapine levels. Inhibitors of CYPIA2 (caffeine, erythrom
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Soyata, Amelia, Aliya Nur Hasanah, and Taofik Rusdiana. "Interaction of Warfarin with Herbs Based on Pharmacokinetic and Pharmacodynamic Parameters." Indonesian Journal of Pharmaceutics 2, no. 2 (2020): 69. http://dx.doi.org/10.24198/idjp.v2i2.27289.

Testo completo
Abstract (sommario):
Warfarin is an oral anticoagulant that has been widely used and has strong efficacy, but the use of warfarin is still a concern because of its narrow therapeutic index which cause interactions when co-administration with drugs, herbs or food. This interaction can affect the pharmacokinetics and pharmacodynamics of warfarin and the most fatal effect from warfarin interactions is bleeding. In this review article data on warfarin-herbs interactions were collected based on pharmacokinetic parameters (AUC0-∞, Cmax, T1/2, Cl/F, and V/F), while pharmacodynamic parameters (International normalized rat
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Costache, Irina-Iuliana, Anca Miron, Monica Hăncianu, Viviana Aursulesei, Alexandru Dan Costache, and Ana Clara Aprotosoaie. "Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products." Cardiovascular Therapeutics 2019 (September 2, 2019): 1–19. http://dx.doi.org/10.1155/2019/9402781.

Testo completo
Abstract (sommario):
The growing use of plant products among patients with cardiovascular pharmacotherapy raises the concerns about their potential interactions with conventional cardiovascular medicines. Plant products can influence pharmacokinetics or/and pharmacological activity of coadministered drugs and some of these interactions may lead to unexpected clinical outcomes. Numerous studies and case reports showed various pharmacokinetic interactions that are characterized by a high degree of unpredictability. This review highlights the pharmacokinetic clinically relevant interactions between major conventional
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Cohen, Lawrence J., and C. Lindsay DeVane. "Clinical Implications of Antidepressant Pharmacokinetics and Pharmacogenetics." Annals of Pharmacotherapy 30, no. 12 (1996): 1471–80. http://dx.doi.org/10.1177/106002809603001216.

Testo completo
Abstract (sommario):
OBJECTIVE: To review available data on pharmacokinetic and pharmacogenetic influences on the response to antidepressant therapy, analyze the mechanisms for and clinical significance of pharmacokinetic and pharmacogenetic differences, and explain the implications of pharmacokinetics and pharmacogenetics for patient care. DATA SOURCES: A MEDLINE search of English-language clinical studies, abstracts, and review articles on antidepressant pharmacokinetics, pharmacogenetics, and drug interactions was used to identify pertinent literature. DATA SYNTHESIS: The pharmacokinetic profiles of selected an
Gli stili APA, Harvard, Vancouver, ISO e altri
6

ERESHEFSKY, LARRY, STEPHEN R. SAKLAD, MARK D. WATANABE, CHESTER M. DAVIS, and MICHAEL W. JANN. "Thiothixene Pharmacokinetic Interactions." Journal of Clinical Psychopharmacology 11, no. 5 (1991): 296???301. http://dx.doi.org/10.1097/00004714-199110000-00004.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Hartshorn, Edward A. "Pharmacokinetic Drug Interactions." Journal of Pharmacy Technology 1, no. 5 (1985): 193–99. http://dx.doi.org/10.1177/875512258500100505.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Eichelbaum, Michel. "Pharmacokinetic Drug Interactions." Journal of Clinical Pharmacology 26, no. 6 (1986): 469–73. http://dx.doi.org/10.1002/j.1552-4604.1986.tb03560.x.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Pukrittayakamee, Sasithon, Joel Tarning, Podjanee Jittamala, et al. "Pharmacokinetic Interactions between Primaquine and Chloroquine." Antimicrobial Agents and Chemotherapy 58, no. 6 (2014): 3354–59. http://dx.doi.org/10.1128/aac.02794-13.

Testo completo
Abstract (sommario):
ABSTRACTChloroquine combined with primaquine has been the standard radical curative regimen forPlasmodium vivaxandPlasmodium ovalemalaria for over half a century. In an open-label crossover pharmacokinetic study, 16 healthy volunteers (4 males and 12 females) aged 20 to 47 years were randomized into two groups of three sequential hospital admissions to receive a single oral dose of 30 mg (base) primaquine, 600 mg (base) chloroquine, and the two drugs together. The coadministration of the two drugs did not affect chloroquine or desethylchloroquine pharmacokinetics but increased plasma primaquin
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Marvanova, Marketa. "Pharmacokinetic characteristics of antiepileptic drugs (AEDs)." Mental Health Clinician 6, no. 1 (2016): 8–20. http://dx.doi.org/10.9740/mhc.2015.01.008.

Testo completo
Abstract (sommario):
Abstract Antiepileptic drugs (AEDs) are routinely prescribed for the management of a variety of neurologic and psychiatric conditions, including epilepsy and epilepsy syndromes. Physiologic changes due to aging, pregnancy, nutritional status, drug interactions, and diseases (ie, those involving liver and kidney function) can affect pharmacokinetics of AEDs. This review discusses foundational pharmacokinetic characteristics of AEDs currently available in the United States, including clobazam but excluding the other benzodiazepines. Commonalities of pharmacokinetic properties of AEDs are discuss
Gli stili APA, Harvard, Vancouver, ISO e altri
Più fonti

Tesi sul tema "Pharmacokinetic interactions"

1

McArdle, Elizabeth Karen. "Pharmacokinetic interactions of constituents of cannabis extracts." Thesis, University of Aberdeen, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415480.

Testo completo
Abstract (sommario):
The use of a whole plant cannabis extract, containing <span style='font-family:Symbol'>D<sup>9</sup>-tetrahydrocannabinol (THC) and cannabidiol (CBD) as the principal constituents, showed statistically significant improvements in the management of multiple sclerosis. Inhibition studies (e.g. IC<sub>50</sub> and K<sub>i</sub> determinations) using phenotyped human liver microsomes and cDNA expressed human P450s (Supersomes<span style='font-family:Symbol'>â demonstrated that CBD competitively inhibits the principal P450s involved in the THC biotransformation, CYP2C9 (K<sub>i</sub> = 0.5 <span st
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Raaska, Kari. "Pharmacokinetic interactions of clozapine in hospitalized patients." Helsinki : University of Helsinki, 2003. http://ethesis.helsinki.fi/julkaisut/laa/kliin/vk/raaska/.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Lundahl, Anna. "In vivo Pharmacokinetic Interactions of Finasteride and Identification of Novel Metabolites." Doctoral thesis, Uppsala universitet, Institutionen för farmaci, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-129362.

Testo completo
Abstract (sommario):
The general aim of this thesis was to improve the understanding of the in vivo pharmacokinetics and, in particular, the metabolism of finasteride, a 5α-reductase inhibitor used in the treatment of enlarged prostate glands and male pattern baldness. CYP3A4 has been identified as the major enzyme involved in the sequential metabolism of finasteride to ω-OH finasteride (M1) and ω-COOH finasteride (M3). The consequences of induced and inhibited metabolism on the pharmacokinetics of finasteride and its metabolites were investigated in humans and pigs. Both studies included bile collection. The coll
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Adedoyin, A. P. "Pharmacokinetic drug-drug interactions : inhibition and induction studies in the rat." Thesis, University of Manchester, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.376236.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Elsherbiny, Doaa. "Pharmacokinetic drug-drug interactions in the management of malaria, HIV and tuberculosis." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-8426.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Yadav, Jaydeep. "EVALUATING PHARMACOKINETIC DRUG-DRUG INTERACTIONS DUE TO TIME DEPENDENT INHIBITION OF CYTOCHROME P450s." Diss., Temple University Libraries, 2018. http://cdm16002.contentdm.oclc.org/cdm/ref/collection/p245801coll10/id/524248.

Testo completo
Abstract (sommario):
Pharmaceutical Sciences<br>Ph.D.<br>Time-dependent inactivation (TDI) of CYPs is a leading cause of clinical drug-drug interactions (DDIs). Current methods tend to over-predict DDIs. In this study, a numerical approach was used to model complex CYP3A TDI in human liver microsomes. Inhibitors evaluated include troleandomycin (TAO), erythromycin (ERY), verapamil (VER), Paroxetine (PAR), itraconazole (ITZ) and diltiazem (DTZ) along with primary metabolites N-demethyl erythromycin (NDE), norverapamil (NV), and N-desmethyl diltiazem (MA). Complexities incorporated in the models included multiple bi
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Cherkaoui, Rbati Mohammed. "Mathematical and physical systems biology : application to pharmacokinetic drug-drug interactions and tumour growth." Thesis, University of Nottingham, 2016. http://eprints.nottingham.ac.uk/33719/.

Testo completo
Abstract (sommario):
In this thesis, a multi-scale approach is provided to a pharmacokinetic and a pharmacodynamic problem. The first part of this research provides a realistic mathematical physiological model of the liver to predict drug drug interactions (DDIs). The model describes the geometry of a lobule (liver unit) and integrates the exchange processes, diffusion and active transport, between the hepatocytes and the blood and possible drug-drug interactions such as; reversible inhibition, mechanistic based inhibition (MBI) and enzyme induction. The liver model is subsequently integrated into a PBPK model wit
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Naghmeh, Jabarizadekivi. "A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations." University of Sydney, 2008. http://hdl.handle.net/2123/2471.

Testo completo
Abstract (sommario):
Master of Philosophy<br>Clozapine is a drug of choice for treatment of refractory schizophrenia, which is primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main metabolite. There are reports of wide ranging gastrointestinal side effects associated with clozapine therapy, that result in concomitant administration of proton pump inhibitors to treat acid-related disorders. Omeprazole is an established CYP1A2 inducer, while an in vitro study has shown that rabeprazole is much less potent in this regard. There is no available information about the impact of rabeprazole on C
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Naghmeh, Jabarizadekivi. "A Comparison of the Effect of Omeprazole and Rabeprazole on Clozapine Serum Concentrations." Thesis, The University of Sydney, 2007. http://hdl.handle.net/2123/2471.

Testo completo
Abstract (sommario):
Clozapine is a drug of choice for treatment of refractory schizophrenia, which is primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main metabolite. There are reports of wide ranging gastrointestinal side effects associated with clozapine therapy, that result in concomitant administration of proton pump inhibitors to treat acid-related disorders. Omeprazole is an established CYP1A2 inducer, while an in vitro study has shown that rabeprazole is much less potent in this regard. There is no available information about the impact of rabeprazole on CYP1A2 activity in patien
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Salem, Farzaneh. "Applications of physiologically based pharmacokinetic modelling to prediction of the likelihood of metabolic drug interactions in paediatric population and studying disparities in pharmacokinetics between children and adults." Thesis, University of Manchester, 2014. https://www.research.manchester.ac.uk/portal/en/theses/applications-of-physiologically-based-pharmacokinetic-modelling-to-prediction-of-the-likelihood-of-metabolic-drug-interactions-in-paediatric-population-and-studying-disparities-in-pharmacokinetics-between-children-and-adults(1fdefe9a-037a-4738-b92a-5904a60960db).html.

Testo completo
Abstract (sommario):
Anticipation of drug-drug interactions (DDIs) in the paediatric population are merely based on data generated in adults. Hence decision on avoiding certain combinations or attempts to adjust and manage the doses under combination-therapy are mainly speculative from the knowledge of what occurs in adults. However, due to developmental changes in elimination pathways from birth to adolescents, the assumption of DDIs being similar in adults and children might not be correct. This thesis firstly identifies and quantitatively compares the reported DDIs in paediatric and adult populations through a
Gli stili APA, Harvard, Vancouver, ISO e altri
Più fonti

Libri sul tema "Pharmacokinetic interactions"

1

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-10527-7.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom, eds. Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs. Springer Singapore, 2016. http://dx.doi.org/10.1007/978-981-10-2113-8.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Järvinen, Kristiina. Ocular and systemic absorption of ophthalmic timolol: Effects of pharmacokinetic interactions and eyedrop formulation. University of Kuopio, 1993.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Bartle, W. R., V. Braun, J. M. Dietschy, et al. Regulation of Plasma Low Density Lipoprotein Levels Biopharmacological Regulation of Protein Phosphorylation Calcium-Activated Neutral Protease Microbial Iron Transport Pharmacokinetic Drug Interactions. Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72902-7.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Björn, Lemmer, ed. Chronopharmacology: Cellular and biochemical interactions. M. Dekker, 1989.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

David, Rodrigues A., ed. Drug-drug interactions. 2nd ed. Informa Healthcare, 2008.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Huang, L. Evaluation of the potential pharmacokinetic interaction between naproxen and zidovudine. Ottawa General Hospital, 1991.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Ritschel, W. A. Handbook of basic pharmacokinetics-- including clinical applications. 6th ed. American Pharmacists Association, 2004.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Ritschel, W. A. Handbook of basic pharmacokinetics ... including clinical applications. 7th ed. American Pharmacists Association, 2009.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Ritschel, W. A. Handbook of basic pharmacokinetics-- including clinical applications. 6th ed. American Pharmacists Association, 2004.

Cerca il testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
Più fonti

Capitoli di libri sul tema "Pharmacokinetic interactions"

1

Bartle, W. R., S. E. Walker, and N. E. Winslade. "Pharmacokinetic Drug Interactions." In Progress in Clinical Biochemistry and Medicine. Springer Berlin Heidelberg, 1987. http://dx.doi.org/10.1007/978-3-642-72902-7_5.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Wittwer, Erica D., and Wayne T. Nicholson. "Pharmacokinetic Interactions: Core Concepts." In A Case Approach to Perioperative Drug-Drug Interactions. Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-7495-1_3.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Mukherjee, Biswajit. "Pharmacokinetic Drug–Drug Interactions." In Pharmacokinetics: Basics to Applications. Springer Singapore, 2022. http://dx.doi.org/10.1007/978-981-16-8950-5_7.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Renton, Kenneth W. "Cytokines and Pharmacokinetic Drug Interactions." In Methods in Pharmacology and Toxicology. Humana Press, 2007. http://dx.doi.org/10.1007/978-1-59745-350-9_14.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Kiang, Tony K. L., Kyle John Wilby, and Mary H. H. Ensom. "Pharmacokinetic Drug Interactions Affecting Antimalarials." In Clinical Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antimalarials. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-10527-7_4.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Markowitz, John S., and Kennerly S. Patrick. "Pharmacokinetic and Pharmacodynamic Drug Interactions." In Attention Deficit Hyperactivity Disorder. Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-891-9:529.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

Huang, Shiew-Mei. "Drug-Drug Interactions." In Applications of Pharmacokinetic Principles in Drug Development. Springer US, 2004. http://dx.doi.org/10.1007/978-1-4419-9216-1_10.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Lewis, D. F. V. "Modelling Human Cytochrome P450-Substrate Interactions." In Pharmacokinetic Challenges in Drug Discovery. Springer Berlin Heidelberg, 2002. http://dx.doi.org/10.1007/978-3-662-04383-7_12.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Ieuter, Rachel C. "Pharmacokinetic Drug-Drug Interactions with Warfarin." In Oral Anticoagulation Therapy. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-54643-8_32.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Back, D. J., and M. L’E Orme. "Pharmacokinetic Drug Interactions with Oral Contraceptives." In Steroid Contraceptives and Women’s Response. Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-2445-8_10.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "Pharmacokinetic interactions"

1

Zhong, Xingjian, Yidan Sun, Amish Patel, Mallory M. Moffett, and Allison M. Dennis. "Biostable PbS/CdS/ZnS Quantum Dots for Longitudinal Shortwave Infrared Imaging." In Optical Molecular Probes, Imaging and Drug Delivery. Optica Publishing Group, 2025. https://doi.org/10.1364/omp.2025.otu3e.2.

Testo completo
Abstract (sommario):
PbS/CdS/ZnS quantum dots demonstrate enhanced biostability over PbS/CdS for longitudinal shortwave infrared imaging, enabling non-invasive pharmacokinetic and biodistribution analyses. This optical approach enables close observation of nano-bio interactions in vivo with many fewer study animals.
Gli stili APA, Harvard, Vancouver, ISO e altri
2

Pessina, Daniele, Roberto Andrea Abbiati, Davide Manca, and Maria M. Papathanasiou. "Machine learning-enhanced Sensitivity Analysis for Complex Pharmaceutical Systems." In The 35th European Symposium on Computer Aided Process Engineering. PSE Press, 2025. https://doi.org/10.69997/sct.133428.

Testo completo
Abstract (sommario):
Pharmacokinetic and pharmacodynamic (PK/PD) models are used to predict drug transport in the body and to assess treatment efficacy and optimal dosage. The kinetic parameters embedded in the models, which define transport across body compartments or drug efficacy, can be linked to patient-specific characteristics; understanding the parameter space-model output relationship is critical towards linking patient population heterogeneity to the therapeutic outcome variability. Global Sensitivity Analysis (GSA) is a well-established tool used to examine parameter-to-parameter interactions, shedding l
Gli stili APA, Harvard, Vancouver, ISO e altri
3

Moitra, Abha, Ravi Palla, Luis Tari, and Mukkai Krishnamoorthy. "Semantic Inference for Pharmacokinetic Drug-Drug Interactions." In 2014 IEEE International Conference on Semantic Computing (ICSC). IEEE, 2014. http://dx.doi.org/10.1109/icsc.2014.36.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
4

Egenlauf, Benjamin, Johanna Ohnesorge, Satenik Harutyunova, et al. "Pharmacokinetic interactions in different combinations of pulmonary arterial hypertension treatment." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2397.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
5

Kulanthaivel, Palaniappan, Daruka Mahadevan, P. Kellie Turner, et al. "Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-ct153.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
6

Hunta, Sathien, and Panchit Longpradit. "Pharmacokinetic simulation for prediction of drug-drug interactions based on agent based modeling." In 2018 International Conference on Digital Arts, Media and Technology (ICDAMT). IEEE, 2018. http://dx.doi.org/10.1109/icdamt.2018.8376508.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
7

KOLCHINSKY, A., A. LOURENÇO, L. LI, and L. M. ROCHA. "EVALUATION OF LINEAR CLASSIFIERS ON ARTICLES CONTAINING PHARMACOKINETIC EVIDENCE OF DRUG-DRUG INTERACTIONS." In Proceedings of the Pacific Symposium. WORLD SCIENTIFIC, 2012. http://dx.doi.org/10.1142/9789814447973_0040.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
8

Schneider, Elena, Patrick Hanafin, and Gauri Rao. "A retrospective observational study: Bidirectional pharmacokinetic interactions between ivacaftor-lumacaftor in cystic fibrosis." In ERS International Congress 2020 abstracts. European Respiratory Society, 2020. http://dx.doi.org/10.1183/13993003.congress-2020.362.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
9

Pawaskar, Dipti K., Robert Straubinger, Gerald Fetterly, Wen Ma, and William Jusko. "Abstract 27: Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-27.

Testo completo
Gli stili APA, Harvard, Vancouver, ISO e altri
10

Beljkas, Milan, Jelena Rebić, Milica Radan, Teodora Đikić, Slavica Oljačić, and Katarina Nikolic. "Virtual Docking, design and in silico ADMET profiling of novel Rho-associated protein kinases-1 (ROCK1) inhibitors." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.589b.

Testo completo
Abstract (sommario):
Overexpression of Rho-associated protein kinases has been associated with various diseases, including tumors. None of the approved ROCK inhibitors are used for cancer treatment. However, some of them have been shown to have anti-tumor potential. The main objective of this study was to develop novel ROCK1 inhibitors using the structure-based method, molecular docking, and prediction of pharmacokinetic properties using the ADMET predictor. The key interactions that strongly correlate with the activity of ROCK1 inhibitors are hydrogen bonds between amino acid residues Met156, Glu154 and the hinge
Gli stili APA, Harvard, Vancouver, ISO e altri

Rapporti di organizzazioni sul tema "Pharmacokinetic interactions"

1

Committee on Toxicology. COT FSA PBPK for Regulators Workshop Report 2021. Food Standards Agency, 2024. http://dx.doi.org/10.46756/sci.fsa.tyy821.

Testo completo
Abstract (sommario):
The future of food safety assessment in the UK depends on the Food Standards Agency’s (FSA) adaptability and flexibility in responding to and adopting the accelerating developments in science and technology. The Tox21 approach is an example of one recent advancement in the development of alternative toxicity testing approaches and computer modelling strategies for the evaluation of hazard and exposure (New Approach Methodologies (NAMs). A key aspect is the ability to link active concentrations in vitro to likely concentrations in vivo, for which physiologically based pharmacokinetic (PBPK) mod
Gli stili APA, Harvard, Vancouver, ISO e altri
Ti possono interessare anche gli elenchi estesi di opere sul tema "Pharmacokinetic interactions":
Articoli di riviste Tesi Libri
Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!

Vai alla bibliografia